Paysign’s Pharma Revenue Jumps 168%, Driving Record Margins and Ambitious 2026 Outlook
Revenue Mix Shift Fuels Record Margins and Top-Line Growth
Paysign, Inc. wrapped up 2025 with a remarkable performance, reporting 40.5% total revenue growth to $82.0 million and demonstrating powerful operating leverage. Most eye-catching was the company’s 167.8% leap in pharmaceutical (pharma) industry revenue, fueled by the addition of 55 net patient affordability programs. This segment is now a powerful earnings engine, outpacing the steady plasma donor compensation business and unlocking much higher margins.
Patient Affordability Becomes Key Profit Engine
The strategic expansion in patient affordability programs led to a 79% increase in processed claims compared to 2024. Pharma revenues grew to $33.89 million in 2025, transforming from around just $12.65 million the year before. This rapid scaling is directly contributing to Paysign’s margin expansion, as gross profit margins climbed to 59.4%, up from 55.1%, while operating margin soared to 9.0%—a dramatic rise from just 1.7% in 2024. Adjusted EBITDA more than doubled, reaching $19.94 million. Net income jumped 97.9% to $7.55 million.
| Metric | 2025 | 2024 | % Change |
|---|---|---|---|
| Total Revenues | $82.03M | $58.38M | +40.5% |
| Pharma Revenue | $33.89M | $12.65M | +167.8% |
| Plasma Revenue | $45.62M | $43.88M | +4.0% |
| Patient Affordability Program Count | 131 | 76 | +72.4% |
| Adjusted EBITDA | $19.94M | $9.62M | +107.3% |
| Net Income | $7.55M | $3.82M | +97.9% |
| Gross Margin | 59.4% | 55.1% | +4.3 pts |
Balance Sheet Strength and Operational Flexibility
Paysign exited the year with $21.07 million unrestricted cash and zero debt, providing a solid foundation for continued platform investment and flexibility to pursue opportunities, as underscored by the recent Gamma Innovation acquisition. Restricted cash—tied to customer programs—also grew by 29% to $143.92 million, supporting the company’s growing reach in the plasma and pharma sectors.
Strong Fourth Quarter Sets the Stage for Acceleration
Q4 2025 was equally robust, with total revenues up 45.8% year-over-year. Pharma revenues in Q4 rose 122% to $9.6 million and patient affordability claim volume increased over 49%. Although net income for the quarter was steady at $1.36 million, operating margin nearly tripled to 8.1%, and Adjusted EBITDA margin soared to 23.9%. All signs point to these positive trends carrying into 2026.
| Quarterly Q4 2025 | Q4 2025 | Q4 2024 | % Change |
|---|---|---|---|
| Total Revenues | $22.76M | $15.61M | +45.8% |
| Pharma Revenue | $9.60M | $4.31M | +122% |
| Plasma Revenue | $12.60M | $10.80M | +16.7% |
| Gross Margin | 57.7% | 58.9% | -1.2 pts |
| Net Income | $1.36M | $1.37M | -0.8% |
| Adjusted EBITDA | $5.43M | $2.86M | +89.6% |
| Adjusted EBITDA Margin | 23.9% | 18.4% | +5.5 pts |
2026 Outlook: Growth Expected to Accelerate Further
Management now forecasts another step-change for 2026, with revenue guidance of $106.5–$110.5 million (30–35% growth), gross margins of 60–62%, and net income projected to nearly double again. The company expects to end Q1 2026 with 137 active patient affordability programs and 589 plasma centers. Adjusted EBITDA is anticipated between $30–$33 million. With both pharma and plasma expected to contribute equally to growth, Paysign enters 2026 with momentum—and management notes the business is still in the early innings of its expansion.
Takeaway: Patient Affordability Programs Drive Paysign’s Re-rating
Paysign’s 2025 performance underscores how scaling in patient affordability can turbocharge growth and margins, turning it from a niche fintech into a platform player in healthcare payments. Investors tracking the intersection of fintech and health services will want to watch Paysign’s execution, particularly as new reimbursement models and pharma partnerships ramp up. The strong balance sheet, diversified revenue mix, and expanding margin profile signal the company is positioning itself for a new phase of accelerated growth—and the early trends for 2026 look favorable.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI